Our expansive research facilities, state-of-the-art technologies and unique location within The Royal Children’s Hospital, are some of the reasons we’re home to over 1,800 leading researchers and scientists.
Stay informed with the latest research insights, technological advancements and innovations in child health from our research and scientific community.
Discover how you can support us and our partners to help our researchers make life-changing breakthroughs for children.
Search throughout the entire MCRI website to find exactly what you are looking for.
Discovering better ways to detect and prevent diseases caused by bacterial pathogens of major global health importance.
Vaccine research, safety and surveillance, and immunisation education. Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC) is a public health partnership initiative of the Victorian Immunisation Program funded by the Department of Health, Victoria.
Our group integrates global disease surveillance with vaccine evaluation to strengthen immunisation strategies worldwide. We work across Australia, Mongolia, Indonesia, Vietnam, Fiji and the broader Asia–Pacific region, as well as some countries in Africa. We partner with governments, research
Our group focuses on understanding infectious diseases and how they impact on reproductive health, women’s health, and the health of infants.
Our vision is to understand the early cellular and molecular origins of childhood health and disease, with a focus on immune and inflammatory conditions.
We address the major treatable and preventable diseases that affect populations in the Asia-Pacific with a focus on equity and the health professionals and systems which deliver care.
Understanding early life influences on infection and consequences for lifelong cardiovascular and metabolic disease risk.
We aim to change the trajectory of global childhood and adult health to reduce the impact of infectious diseases and allergies.
We aim to develop a safe, effective and affordable vaccine to protect babies from severe rotavirus disease from birth. RV3-BB vaccine has now been studied in adults, children, infants and newborns in trials conducted in Australia, New Zealand, Indonesia and Malawi, Africa.
We seek to further the diagnosis, investigation and treatment of children with common childhood illnesses who present to hospital. Our research aims to further the clinical diagnosis, investigation and treatment of children with common childhood infections and other illnesses who present to
Page 152 of 260
